drugset
drugset / Trial / NCT04827875

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

NCT04827875 ↗

Phase 1 Completed 25 enrolled AiViva BioPharma, Inc.
Non-randomizedSequentialOpen-labelPrevention

Summary

To evaluate the saftye and effectiveness of AIV001 treatment on scar formation and/or keloid scar recurrence following keloidectomy.

Timeline

Start
2021-06-23
Primary completion
2022-12-15
Completion
2022-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject AIV001 Unknown — Other

Indications

keloid